NGNE Stock Price
Neurogene Inc.
NGNE stock price is $25.21 (-3.04% on the day), giving Neurogene Inc. a market cap of $504.49M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
NGNE Stock Overview
- Price
- $25.21
- Previous close
- $26.00
- Open
- $25.22
- Market cap
- $504.49M
- 52-week range
- $15.93 - $43.66
- 1-year price target
- $77.22
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- Nasdaq
- MarketXLS Rank
- 42
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company is headquartered in New York, New York.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NGNE | $25.21 | -3.0% | 140.28K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |